Annual CFF
$276.45 M
+$164.86 M+147.74%
31 December 2023
Summary:
Beam Therapeutics annual cash flow from financing activities is currently $276.45 million, with the most recent change of +$164.86 million (+147.74%) on 31 December 2023. During the last 3 years, it has fallen by -$45.87 million (-14.23%). BEAM annual CFF is now -63.44% below its all-time high of $756.14 million, reached on 31 December 2021.BEAM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.26 M
+$1.13 M+848.87%
30 September 2024
Summary:
Beam Therapeutics quarterly cash flow from financing activities is currently $1.26 million, with the most recent change of +$1.13 million (+848.87%) on 30 September 2024. Over the past year, it has dropped by -$35.52 million (-96.57%). BEAM quarterly CFF is now -99.61% below its all-time high of $320.89 million, reached on 30 September 2021.BEAM Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$38.01 M
-$35.52 M-48.31%
30 September 2024
Summary:
Beam Therapeutics TTM cash flow from financing activities is currently $38.01 million, with the most recent change of -$35.52 million (-48.31%) on 30 September 2024. Over the past year, it has dropped by -$236.74 million (-86.17%). BEAM TTM CFF is now -95.60% below its all-time high of $864.59 million, reached on 30 September 2021.BEAM TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BEAM Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +147.7% | -96.6% | -86.2% |
| 3 y3 years | -14.2% | -99.6% | -95.6% |
| 5 y5 years | +53.8% | -53.1% | -6.3% |
BEAM Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -63.4% | +147.7% | -99.6% | +848.9% | -95.6% | at low |
| 5 y | 5 years | -63.4% | +569.7% | -99.6% | +262.0% | -95.6% | at low |
| alltime | all time | -63.4% | +569.7% | -99.6% | +262.0% | -95.6% | +0.3% |
Beam Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.26 M(+848.9%) | $38.01 M(-48.3%) |
| June 2024 | - | $133.00 K(-95.4%) | $73.52 M(-59.4%) |
| Mar 2024 | - | $2.90 M(-91.4%) | $180.93 M(-34.6%) |
| Dec 2023 | $276.45 M(+147.7%) | $33.71 M(-8.3%) | $276.45 M(+0.6%) |
| Sept 2023 | - | $36.78 M(-65.8%) | $274.75 M(+14.7%) |
| June 2023 | - | $107.54 M(+9.3%) | $239.53 M(+55.2%) |
| Mar 2023 | - | $98.42 M(+207.4%) | $154.33 M(+38.3%) |
| Dec 2022 | $111.59 M(-85.2%) | $32.01 M(+1949.4%) | $111.59 M(+10.4%) |
| Sept 2022 | - | $1.56 M(-93.0%) | $101.12 M(-75.9%) |
| June 2022 | - | $22.34 M(-59.9%) | $420.44 M(-24.7%) |
| Mar 2022 | - | $55.68 M(+158.4%) | $558.54 M(-26.1%) |
| Dec 2021 | $756.14 M | $21.54 M(-93.3%) | $756.14 M(-12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $320.89 M(+100.0%) | $864.59 M(+59.0%) |
| June 2021 | - | $160.44 M(-36.7%) | $543.80 M(+42.1%) |
| Mar 2021 | - | $253.27 M(+94.8%) | $382.58 M(+18.7%) |
| Dec 2020 | $322.32 M(+680.8%) | $129.99 M(>+9900.0%) | $322.32 M(+67.0%) |
| Sept 2020 | - | $94.00 K(-112.1%) | $193.03 M(-1.3%) |
| June 2020 | - | -$779.00 K(-100.4%) | $195.63 M(-0.4%) |
| Mar 2020 | - | $193.01 M(>+9900.0%) | $196.38 M(+375.8%) |
| Dec 2019 | $41.28 M(-77.0%) | $699.00 K(-74.0%) | $41.28 M(+1.7%) |
| Sept 2019 | - | $2.69 M(<-9900.0%) | $40.58 M(+7.1%) |
| June 2019 | - | -$20.00 K(-100.1%) | $37.89 M(-0.1%) |
| Mar 2019 | - | $37.91 M | $37.91 M |
| Dec 2018 | $179.73 M | - | - |
FAQ
- What is Beam Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Beam Therapeutics?
- What is Beam Therapeutics annual CFF year-on-year change?
- What is Beam Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Beam Therapeutics?
- What is Beam Therapeutics quarterly CFF year-on-year change?
- What is Beam Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Beam Therapeutics?
- What is Beam Therapeutics TTM CFF year-on-year change?
What is Beam Therapeutics annual cash flow from financing activities?
The current annual CFF of BEAM is $276.45 M
What is the all time high annual CFF for Beam Therapeutics?
Beam Therapeutics all-time high annual cash flow from financing activities is $756.14 M
What is Beam Therapeutics annual CFF year-on-year change?
Over the past year, BEAM annual cash flow from financing activities has changed by +$164.86 M (+147.74%)
What is Beam Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BEAM is $1.26 M
What is the all time high quarterly CFF for Beam Therapeutics?
Beam Therapeutics all-time high quarterly cash flow from financing activities is $320.89 M
What is Beam Therapeutics quarterly CFF year-on-year change?
Over the past year, BEAM quarterly cash flow from financing activities has changed by -$35.52 M (-96.57%)
What is Beam Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BEAM is $38.01 M
What is the all time high TTM CFF for Beam Therapeutics?
Beam Therapeutics all-time high TTM cash flow from financing activities is $864.59 M
What is Beam Therapeutics TTM CFF year-on-year change?
Over the past year, BEAM TTM cash flow from financing activities has changed by -$236.74 M (-86.17%)